Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study.

Richard A FurieDouglas R HoughAllison GaudyYing YeShimon KorishNikolay DelevMichael WeiswasserXiaojiang ZhanPeter H SchaferVictoria P Werth

Published in: Lupus science & medicine (2022)

These proof-of-concept findings suggest a favourable benefit/risk ratio in SLE for iberdomide, a drug with a novel immunomodulatory mechanism of action, supporting further clinical investigation.

Keyphrases

placebo controlled
double blind
clinical trial
systemic lupus erythematosus
phase iii
phase ii
study protocol
phase ii study
disease activity
pulmonary artery
adverse drug
emergency department
squamous cell carcinoma
rheumatoid arthritis
drug induced